Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

CONTEXT -The National Cancer Care Network and the combined College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines indicate that all lung adenocarcinomas (ADCs) should be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. As the majority of patients present at a later stage, the subclassification and molecular analysis must be done on cytologic material. OBJECTIVE -To evaluate the accuracy and interobserver variability among cytopathologists in subtyping non-small cell lung carcinoma using cytologic preparations. DESIGN -Nine cytopathologists from different institutions submitted cases of non-small cell lung carcinoma with surgical follow-up. Cases were independently, blindly reviewed by each cytopathologist. A diagnosis of ADC or squamous cell carcinoma was rendered based on the Diff-Quik, Papanicolaou, and hematoxylin-eosin stains. The specimen types included fine-needle aspiration from lung, lymph node, and bone; touch preparations from lung core biopsies; bronchial washings; and bronchial brushes. A major disagreement was defined as a case being misclassified 3 or more times. RESULTS -Ninety-three cases (69 ADC, 24 squamous cell carcinoma) were examined. Of 818 chances (93 cases × 9 cytopathologists) to correctly identify all the cases, 753 correct diagnoses were made (92% overall accuracy). Twenty-five of 69 cases of ADC (36%) and 7 of 24 cases of squamous cell carcinoma (29%) had disagreement (P = .16). Touch preparations were more frequently misdiagnosed compared with other specimens. Diagnostic accuracy of each cytopathologist varied from 78.4% to 98.7% (mean, 91.7%). CONCLUSION -Lung ADC can accurately be distinguished from squamous cell carcinoma by morphology in cytologic specimens with excellent interobserver concordance across multiple institutions and levels of cytology experience.

[1]  N. Rekhtman,et al.  Depletion of Core Needle Biopsy Cellularity and DNA Content as a Result of Vigorous Touch Preparations. , 2015, Archives of pathology & laboratory medicine.

[2]  S. H. Omland,et al.  Subtyping of nonsmall cell lung cancer on cytology specimens: Reproducibility of cytopathologic diagnoses on sparse material , 2014, Diagnostic cytopathology.

[3]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  H. Lee,et al.  NSCLC subtype prediction using cytologic fluid specimens from needle aspiration biopsies. , 2013, American journal of clinical pathology.

[5]  M. Tsao,et al.  Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. , 2012, Lung cancer.

[6]  Congli Wang,et al.  Non-Small-Cell Lung Carcinoma Subtyping on Cytology without the Use of Immunohistochemistry – Can We Meet the Challenge? , 2012, Acta Cytologica.

[7]  H. Kimbrell,et al.  Subclassification of Non-Small Cell Lung Cancer by Cytologic Sampling: A Logical Approach with Selective Use of Immunocytochemistry , 2012, Acta Cytologica.

[8]  J. Jagirdar,et al.  Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. , 2012, Archives of pathology & laboratory medicine.

[9]  W. Travis,et al.  Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Mattia Barbareschi,et al.  Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine‐needle aspiration cytology , 2011, Cancer.

[11]  S. Dacic,et al.  Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. , 2011, American journal of clinical pathology.

[12]  A. Ardizzoni,et al.  Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  A. Ardizzoni,et al.  First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype , 2009, Expert review of anticancer therapy.

[15]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[16]  C. Gridelli.  Histology-based treatment: a new scenario in the management of advanced nonsmall cell lung cancer. , 2009, Current opinion in oncology.

[17]  G. Demetri,et al.  NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. , 1996, Oncology.